# OnCo record thyroid-cancer-signalling (pathway). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/pathways/thyroid-cancer-signalling/>
  a schema:BioChemEntity ;
  onco:kind "pathway" ;
  schema:identifier "thyroid-cancer-signalling" ;
  schema:name "Thyroid cancer (KEGG map)"@en ;
  schema:alternateName "KEGG hsa05216"@en, "Thyroid cancer"@en ;
  schema:description "This KEGG map shows thyroid cancers driven by one relay, the MAPK pathway: RET or NTRK fusions and BRAF mutations in papillary tumours, RAS mutations or PAX8-PPARG fusion in follicular tumours, and TP53 loss marking anaplastic cancer. It matters because RET, NTRK and BRAF alterations each have their own drug, and MAPK blockade can restore iodine uptake."@en ;
  schema:url <https://onco.cc/pathways/thyroid-cancer-signalling/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.kegg.jp/pathway/hsa05216>, <https://doi.org/10.1016/S0140-6736(16)30172-6> ;
  onco:related <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/rtk-activation/> ;
  onco:cancers <https://onco.cc/cancers/thyroid/> ;
  onco:targets <https://onco.cc/targets/ret/>, <https://onco.cc/targets/ntrk/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/braf/>, <https://onco.cc/targets/mek/>, <https://onco.cc/targets/tp53/> ;
  onco:drugs <https://onco.cc/drugs/selpercatinib/>, <https://onco.cc/drugs/pralsetinib/>, <https://onco.cc/drugs/vandetanib/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/larotrectinib/>, <https://onco.cc/drugs/entrectinib/>, <https://onco.cc/drugs/repotrectinib/>, <https://onco.cc/drugs/dabrafenib/>, <https://onco.cc/drugs/trametinib/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/sorafenib/>, <https://onco.cc/drugs/selumetinib/>, <https://onco.cc/drugs/radioactive-iodine/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/>, <https://onco.cc/pathways/rtk-activation/>, <https://onco.cc/pathways/p53-cell-cycle/>, <https://onco.cc/pathways/wnt/>, <https://onco.cc/pathways/emt/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-cabanillas-lancet/> .